News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
693,626 Results
Type
Article (39429)
Company Profile (249)
Press Release (653948)
Section
Business (204048)
Career Advice (2006)
Deals (35409)
Drug Delivery (93)
Drug Development (80965)
Employer Resources (169)
FDA (16139)
Job Trends (14832)
News (344925)
Policy (32479)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2538)
Accelerated approval (2)
Adcomms (20)
Allergies (77)
Alliances (49331)
ALS (74)
Alzheimer's disease (1321)
Antibody-drug conjugate (ADC) (98)
Approvals (16126)
Artificial intelligence (209)
Autoimmune disease (10)
Automation (14)
Bankruptcy (357)
Best Places to Work (11637)
BIOSECURE Act (18)
Biosimilars (92)
Biotechnology (177)
Bladder cancer (50)
Brain cancer (23)
Breast cancer (231)
Cancer (1781)
Cardiovascular disease (132)
Career advice (1670)
Career pathing (28)
CAR-T (130)
Cell therapy (372)
Cervical cancer (13)
Clinical research (65367)
Collaboration (694)
Compensation (383)
Complete response letters (18)
COVID-19 (2568)
CRISPR (31)
C-suite (174)
Cystic fibrosis (97)
Data (1703)
Decentralized trials (2)
Denatured (14)
Depression (35)
Diabetes (222)
Diagnostics (6300)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (102)
Drug pricing (93)
Drug shortages (23)
Duchenne muscular dystrophy (62)
Earnings (85685)
Editorial (27)
Employer branding (21)
Employer resources (145)
Events (111151)
Executive appointments (586)
FDA (17096)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (625)
Gene editing (84)
Generative AI (18)
Gene therapy (255)
GLP-1 (658)
Government (4363)
Grass and pollen (4)
Guidances (44)
Healthcare (18783)
Huntington's disease (22)
IgA nephropathy (19)
Immunology and inflammation (88)
Indications (23)
Infectious disease (2686)
Inflammatory bowel disease (124)
Inflation Reduction Act (8)
Influenza (43)
Intellectual property (69)
Interviews (311)
IPO (16468)
IRA (39)
Job creations (3627)
Job search strategy (1421)
Kidney cancer (9)
Labor market (26)
Layoffs (441)
Leadership (14)
Legal (7890)
Liver cancer (68)
Lung cancer (259)
Lymphoma (119)
Machine learning (2)
Management (57)
Manufacturing (243)
MASH (57)
Medical device (13281)
Medtech (13286)
Mergers & acquisitions (19339)
Metabolic disorders (575)
Multiple sclerosis (58)
NASH (16)
Neurodegenerative disease (68)
Neuropsychiatric disorders (23)
Neuroscience (1744)
NextGen: Class of 2025 (6510)
Non-profit (4476)
Northern California (2200)
Now hiring (35)
Obesity (316)
Opinion (196)
Ovarian cancer (61)
Pain (68)
Pancreatic cancer (68)
Parkinson's disease (116)
Partnered (17)
Patents (176)
Patient recruitment (79)
Peanut (45)
People (56900)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20354)
Phase II (28791)
Phase III (21441)
Pipeline (799)
Podcasts (39)
Policy (97)
Postmarket research (2563)
Preclinical (8590)
Press Release (64)
Prostate cancer (84)
Psychedelics (30)
Radiopharmaceuticals (242)
Rare diseases (332)
Real estate (5897)
Recruiting (64)
Regulatory (21985)
Reports (43)
Research institute (2314)
Resumes & cover letters (349)
Rett syndrome (2)
RNA editing (1)
RSV (36)
Schizophrenia (58)
Series A (113)
Series B (68)
Service/supplier (11)
Sickle cell disease (49)
Southern California (1879)
Special edition (13)
Sponsored (28)
Startups (3569)
State (2)
Stomach cancer (11)
Supply chain (55)
The Weekly (24)
United States (19285)
Vaccines (622)
Venture capitalists (34)
Webinars (12)
Weight loss (214)
Women's health (30)
Worklife (13)
Date
Today (187)
Last 7 days (791)
Last 30 days (2874)
Last 365 days (34351)
2025 (5522)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (717)
Alabama (48)
Alaska (7)
Arizona (211)
Arkansas (12)
Asia (37554)
Australia (6140)
California (5002)
Canada (1757)
China (413)
Colorado (229)
Connecticut (238)
Delaware (110)
Europe (80511)
Florida (739)
Georgia (172)
Idaho (57)
Illinois (464)
India (20)
Indiana (272)
Iowa (7)
Japan (126)
Kansas (99)
Kentucky (23)
Louisiana (7)
Maine (59)
Maryland (765)
Massachusetts (3802)
Michigan (201)
Minnesota (345)
Mississippi (2)
Missouri (70)
Montana (27)
Nebraska (25)
Nevada (54)
New Hampshire (61)
New Jersey (1413)
New Mexico (27)
New York (1429)
North Carolina (861)
North Dakota (7)
Northern California (2200)
Ohio (176)
Oklahoma (13)
Oregon (32)
Pennsylvania (1137)
Puerto Rico (6)
Rhode Island (23)
South America (1093)
South Carolina (13)
South Dakota (1)
Southern California (1879)
Tennessee (83)
Texas (729)
Utah (155)
Virginia (116)
Washington D.C. (54)
Washington State (478)
West Virginia (3)
Wisconsin (44)
693,626 Results for "qualigen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Qualigen to participate in next funding round for NanoSynex
January 28, 2025
·
4 min read
Deals
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
Qualigen Therapeutics, Inc. announced today that on May 23, 2024, it received written notice (the “Delist Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating the Company’s continued non-compliance with the minimum bid price requirement, pursuant to Listing Rule 5550(b)(2).
May 30, 2024
·
5 min read
Press Releases
Qualigen Therapeutics, Inc. Announces management changes.
September 27, 2024
·
3 min read
Press Releases
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
September 20, 2024
·
2 min read
Business
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Marizyme, Inc. (“Marizyme”, OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™.
April 16, 2024
·
4 min read
Business
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
September 6, 2024
·
4 min read
Press Releases
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering
September 5, 2024
·
4 min read
Press Releases
Qualigen Therapeutics Announces Regained Compliance with Nasdaq’s Minimum Bid Price Requirement and the Equity Requirement
December 5, 2024
·
2 min read
Press Releases
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares
November 19, 2024
·
3 min read
Biotech Beach
Qualigen Therapeutics’ Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
April 10, 2024
·
3 min read
1 of 69,363
Next
